Time-saving purification solutions for life-changing work

The POROS resin technology is first developed. The innovative bead features large through pores for improved process efficiency. The rigid, incompressible bead can withstand higher flow rates and is smaller than standard agarose beads, which leads to superior resolution properties.

The first POROS chromatography products launch: POROS HS and POROS HQ ion exchange chromatography resins. These cation and anion exchange resins are the first in their class featuring high dynamic binding capacity over a wide range of process conditions.

Researchers first identify Camelid single-domain antibodies. These unique antibodies form the basis of the CaptureSelect affinity technology, the first of its kind and currently the most comprehensive affinity ligand library and affinity resin portfolio in the world.

A POROS resin is used for the commercial manufacturing of a therapeutic antibody targeted against CD20, a surface antigen present in B-cells. This anti-CD20 antibody can be used to treat auto-immune diseases and certain types of cancer.

CaptureSelect Human Albumin Affinity Matrix is used for the capture of human serum albumin and albumin fusion proteins.

POROS products are used in the commercial manufacture of a therapeutic antibody against RSV protein F, a treatment that protects high-risk babies from deadly Respiratory Syncytial Virus (RSV) infections.

Thermo Scientific POROS HS cation exchange resin is used in the development of a human papillomavirus (HPV) virus-like particle vaccine. The vaccine is used to prevent cervical cancer in young women, caused by HPV infection.

POROS is used in the commercial manufacturing process of a therapeutic antibody against VEGF-A (vascular endothelial growth factor A), which functions as an angiogenesis inhibitor. The therapy is used as a supporting drug in various types of cancer and to treat a specific eye disease.

A major improvement on traditional cation exchangers, the newly launched Thermo Scientific POROS XS resin sets the standard for cation exchange chromatography. POROS XS is a strong anion exchange resin with increased capacity and high resolution.

First CaptureSelect resin was launched for the purification of therapeutic FSH (follicle-stimulating hormone). FSH plays an important role in the reproductive process.

A type of cancer immunotherapy uses a therapeutic monoclonal antibody that blocks the PD-1 receptor, a checkpoint inhibitor protein present on the surface of T- and B-cells.

Thermo Fisher launches the antibody affinity resin portfolio, developed to overcome purification challenges associated with novel antibody formats. These resins are the alternative solution when Protein A doesn’t yield acceptable results.

Recombinant FVIII, an innovative hemophilia biotherapeutic, approved using CaptureSelect technology in its manufacturing process.

Launched the Thermo Scientific POROS XQ resin—a next-generation, high-capacity, high-resolution, salt-tolerant strong anion exchange resin that allows loading to more than 140 mg/mL capacity in the presence of higher salt while delivering exceptional separation capability.

By combining the two novel technologies, a unique purification solution for AAV vectors is launched. CaptureSelect AAV8 and AAV9 affinity resins address the purification challenges of AAV development, a vector broadly used in gene therapy.

Launch of POROS hydrophobic interaction chromatography family. Covering a wide range of hydrophobicities, these high performance bioprocess resins are engineered for improved impurity removal during large-scale downstream purification of biomolecules.

Introduction of POROS CaptureSelect AAVX Affinity Resin, a universal capture resin for AAV vector purification. The launch of POROS CaptureSelect AAVX is an extension of the AAV purification portfolio, engineered to purify a broad range of naturally occurring and synthetic AAV serotypes used for gene therapies—from AAV1 to AAV9, AAVrh10, and chimeric vectors.

CaptureSelect C-Tag affinity matrix is used in the downstream process of a protein-based malaria vaccine used in clinical trials.

Launch of POROS Oligo (dT)25, designed for the purification and isolation of mRNA from in vitro transcription manufacturing processes. The resin effectively separates mRNA from components of the transcription reaction process, such as enzymes and plasmid DNA.

A recombinant Factor VII product, used to treat a rare blood clotting disorder, is approved using CaptureSelect technology for manufacturing.

Launch of the first POROS CaptureSelect resin which can be used for the removal of Clusterin, a host cell protein that is difficult to remove.

Launch of CaptureSelect products featuring CD4 and CD8 ligands for the isolation of specific subsets of T-cells.

A high-performance Protein A resin, Thermo Scientific POROS MabCaptureC affinity resin is launched. Designed with high capacity and excellent alkaline stability, this resin offers efficient process-scale purification of monoclonal antibodies.

To meet the demands of complex monoclonal antibody purification development and manufacturing, the Thermo Scientific POROS Caprylate Cation Exchange Chromatography Resin is released. This resin helps boost purification through the combined principles of both ion exchange and hydrophobic interactions.